A new study conducted by researchers at the Institute of Psychiatry, Psychology & Neuroscience has found that psilocybin can be administered safely to six participants at the same time, at doses of either 25 mg or 10 mg. Psilocybin is a naturally occurring hallucinogenic compound found in certain mushrooms that grow in Mexico, South America, Europe and the United States.
The research has demonstrated the viability and safety of psilocybin for use in controlled settings in combination with therapy as a possible treatment for various mental health disorders, including post-traumatic stress disorder and treatment-resistant depression. The treatments currently used to manage these conditions are partially or completely ineffective for many individuals, which has resulted in a significant unmet need.
Early studies have shown a potential for psilocybin therapy in treating these individuals. However, no trials have been conducted at the scale required for regulatory approval that will make the therapy available. This study is the first to look into the simultaneous administration of psilocybin.
For their study, the researchers recruited 89 healthy participants who hadn’t used psilocybin in at least 12 months. Of this number, they randomly picked 60 individuals to receive either a 25 mg or 10 mg dose of psilocybin. The remaining 29 were the control group and were administered with a placebo. All the participants received support from trained psychotherapists after the drug/placebo was administered.
The researchers closely monitored the participants who had received psilocybin for six to eight hours before following up with them for 12 weeks. During this period, the researchers evaluated the participants for potential changes, including sustained planning, memory and attention as well as their ability to process their emotions. The researchers recorded no instances of participants withdrawing from the trial because of the occurrence of an adverse event, noting that they also observed no consistent trends suggesting that either of the psilocybin doses administered had detrimental effects on participants.
Lead author of the study Dr. James Rucker stated that the research was an important demonstration that the administration of psilocybin could be further explored, noting that demonstrating the safety and feasibility of administering the drug to more than one individual simultaneously could help find ways to scale up the treatment. Rucker is a research clinical scientist at the National Institute for Health as well as an honorary consultant psychiatrist at Maudsley NHS Foundation Trust. The study was carried out in partnership with Compass Pathways and its findings were published in the “Journal of Psychopharmacology.”
With the high rate at which science-based support for the therapeutic use of psychedelics is accumulating, it may not be long before various remedies developed by sector players such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are readily available wherever patients need them.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.